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1. Introduction
Retinopathy of prematurity (ROP) is a disease of premature infants and a leading worldwide
cause of child blindness [1]. An epidemic of ROP occurred between 1941 and 1953, when an
estimated 12,000 infants in affluent countries suffered visual loss from ROP. The first case of
ROP, known then as retrolental fibroplasia (RLF), was identified in 1942 [2] with likely total
retinal detachment [1]. However, RLF is currently applied to describe later stage cicatricial
(severe retinal scarring) disease with retinal detachment and formation of retrolental fibro‐
plastic membrane [2]. It is likely that the severe, advanced disease stage of RLF would have
been more readily identifiable in 1942, in the absence of technological advancements that have
added precision and clarity to ophthalmic diagnosis. Cases of ROP were reported throughout
the developed world over the following decade. Intensive oxygen therapy as the key deter‐
minant of ROP was not known until the early 1950s when the suggestion of oxygen toxicity in
ROP was made.
ROP is a biphasic condition comprising an initial phase of vessel growth retardation followed
by a second phase of vessel proliferation characterised by abnormal retinal vasculature
development [2]. Broadly it is thought to be caused by disorganised blood vessel growth that
may result in scarring of the retina and retinal detachment.
The precise aetiology of ROP remains unclear [1]. Onset is associated with immaturity. The
three factors that have shown a consistently significant association with retinopathy of
prematurity are low birth weight, low gestational age and prolonged supplementary oxygen
exposure after delivery [3].
© 2014 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
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The pathological process includes several risk factors that impact on each other. These include
premature birth, multiple gestation, prenatal complications, genetic factors, immature
pulmonary function, intraventricular haemorrhage, sepis, anaemia, patent ductus arteriosus,
growth factors, prostaglandin synthetase inhibitors, vitamin E deficiency, lactic acidosis [1,23],
vasoactive substances development of retinal vessels, maturation of retinal cells with subse‐
quent growth of metabolic demands and the state of the antioxidant system. The exact role of
these remains undetermined [3].
ROP is one of the few preventable causes of childhood visual impairment [5]. Early identifi‐
cation and treatment prevent blindness and offer the affected child better visual development
[6]. Thus, new, innovative evidence-based approaches to the investigation, screening, preven‐
tion and treatment of ROP are still required [1].
2. Epidemiology
Increases in the incidence and prevalence of ROP became recognised as specialists began to
theorise that oxygen toxicity might be a contributory factor in pathology among premature
babies [1,23] this leading to a perceived ‘epidemic’ of ROP. Two epidemics of ROP have
occurred in the last 70 years in the developed world. The first occurred in 1941-53. This was
thought to be related to hyperoxia from incubators[7].
Subsequent research has confirmed that high blood level oxygen causes obliteration of retinal
vessels [24-26]. Based on this, recommendations to lower oxygen supply were undertaken and
the levels of ROP declined dramatically. Consequently, incubator oxygen concentrations,
frequency of administration and duration of oxygen therapy became reduced in many neonatal
units throughout the developed world [31].
In the 1970-80s, despite closer oxygen supply monitoring, a second epidemic was recorded,
with more extreme low birth weight infants surviving in developed countries [8].
Currently it is thought a possible third epidemic is occurring in industrial medium-developed
countries, with several explanations attributable [9-10]. Firstly, there is a higher ratio of
premature born to newborns owing to progress in neonatology. The survival of extremely low
birth weight infants has increased from 5% to 65% in the last 40 years. Whilst compulsory
screening is available in some countries like those of the UK, this is no longer the case in other
western countries owing to lack of resources and adequate training. This means that there are
a higher number of advanced ROP cases in immature and mature children.
The incidence of the disease was first reviewed in the Cryotherapy for Retinopathy of Prema‐
turity Cooperative Group (CRYO-ROP) study, based on a multicentre trial in the United States.
9751 infants from 23 centres were recruited, and 65.8% of those premature babies with a birth-
weight less than 1251 grams were noted to have some form of ROP. 18% developed stage 3
disease and 6% were treated [11].
The Early Treatment of ROP study (ET-ROP) study [12] looked at 317 newborns from 26
different centres with birth weight less than 1251 grams. The incidence was very similar at
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68%, and was noted to decrease sharply with increasing birth weight and gestational age.
Other trials have been undertaken, but have used different criteria (notable birth weight)
to these trials listed,  meaning a direct  comparison is  futile.  These trials are listed in the
table 1 below [13-19].
author age (weeks of gestation) weight (grams) incidence %
Al Amro2003 <37 <2000 3.4
Hussan1999 <1500 21.3
Fortes, 2007 <36 <1000 48.9
<1500 16.2
Good 2005 <1251 68
Shah 2005 <1500 29.2
Martin Begué 2003 <1501 29.2
Rehka, 1996 <34 <1500 46%
Table 1. Trials undertaken for incidence retinopathy of prematurity looking at the gestational age and weight
3. Classification
The International Classification of Retinopathy of Prematurity (ICROP) was devised by expert
ophthalmologists in the field from 11 countries to help more suitably describe the observations
of the disease. This was designed to help clarify what stage of disease was being treated, and
to help audit results of treatment. The original ICROP was devised in 1984 [20], with subse‐
quent minor revision in 1987 [21] and with enhanced imaging techniques further modification
in 2005 [22].
The classification system has always been based on 3 basic paradigms; location, extent and
staging of the disease.
3.1. Location
The original classification in 1984 describes 3 concentric zones of retinal involvement to define
the antero-posterior location of the retinopathy. Each zone is centered on the optic disc rather
than the macula, since normal retinal growth proceeds forward from the optic disc towards
the ora serrata in a systematic fashion (although it is observed that the extent of retinal
vascularisation and ROP may be observed closer to the optic disc nasally than temporally).
Zone I (posterior pole or inner zone consists of a circle), the radius of which extends from the
centre of the optic disc to twice the distance from the centre of the optic disc to the centre of
the macula. The radius of this zone subtends an angle of 30 degrees. The limits of the zone are
consequently defined as twice the disc-foveal distance in all directions from the optic disc; an
arc of 60 degrees.
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Zone II is the area extending from the edge of zone I peripherally to a point tangential to the
nasal ora serrata (at the 3 o clock position in the right eye and the 9 o clock position in the left
eye. The temporal edge of zone II cannot be more accurately defined as the anatomic landmarks
needed to identify the equator in premature infants are obscured.
Zone III is the residual crescent of retina anterior to zone II. By convention zones I and II are
considered mutually exclusive. Retinopathy of prematurity should be considered in zone II
until it can be confirmed that the nasal most 2 clock hours are vascularised to the ora serrata.
For the clinician as a practical approach, using a 25D or 28 diopter (D) condensing lens can
help to determine the approximate temporal extent of zone I. The limit of zone I is at the
temporal field of view by placing the nasal edge of the optic disc at one edge of the field of
view.
3.2. Extent
The extent of the disease specified as the hours of the clock or as 30 degree sectors. As the
observer looks at each eye, the 3o’clock position is to the right and nasal in the right eye and
temporal in the left eye. The 9 o’clock position is to the left and temporal in the right eye and
nasal in the right eye.
3.3. Staging of the disease
This refers to the amount of abnormal vascular response observed. Prior to ROP development
in the premature infant, vascularisation of the retina is incomplete. There are now 5 stages
used to describe the abnormal vascular response at the junction of the vascularised and
avascular retina. Initially the ICROP had 4 stages, but this has been modified to 5 stages for
the eye as a whole, based on the most severe manifestation present since more than one ROP
stage may be present in the same eye. For the purpose of recording the examination, each stage
is defined and the extent of clock hours is recorded.
Stage 1: Demarcation line
This is a thin but destructive structure separating the avascular anteriorly and vascular retina
posteriorly. There is abnormal arcading or branching of vessels leading up to the demarcation
line that is relatively flat, white, and lies within the plane of the retina. Vascular changes can
be apparent prior to the development of the demarcation line, such as dilatation rather than
tapering of the peripheral retinal vessels, but these changes are subtle and different to quantify,
inadequate for diagnosing early ROP.
Stage 2: Ridge
This is the hallmark of stage 2 ROP. It arises in the region of the demarcation line that has now
grown, has height and width, and extends above the plane of the retina. The ridge may change
colour from white to pink and vessels may leave the plane of the retina to enter it. Small isolated
tufts of new vessels lying on the surface of the retina may be seen posterior to this ridge
structure. They do not make part of the growth necessary for stage 3. These small isolated tufts
are commonly referred to as ‘popcorn’.
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Stage 3: Extraretinal fibrovascular proliferation
In stage 3 extraretinal fibrovascular retinal proliferation tissue develops from the ridge and
extends into the vitreous. This extraretinal proliferating tissue is has 3 characteristics; first it is
continuous with the posterior aspect of the ridge, causing a ragged appearance as the prolif‐
eration becomes more extensive. Second, it is immediately posterior to the ridge but not always
appearing to be connected with it. Third it projects theinto the vitreous perpendicular to the
retinal plane. The severity of a stage 3 disease can be subdivided into mild, moderate or severe
depending on the extent of the extraretinal fibrovascular tissue infiltrating the vitreous.
Stage 4: Partial Retinal Detachment
Stage 4 is divided into extrafoveal (stage 4A) and foveal (stage 4B) partial retinal detachments.
This may be caused by exudative effusion of fluid, traction or both. These are generally concave
and most tend to be circumferentially orientated. The extent of retinal detachment depends
on the number of clock hours of fibrovascular traction and their degree of contraction.
Typically, retinal detachments begin at the point of fibrovacular attachment to the vascularised
retina. In progressive cases, the fibrous tissue continues to contract and the tractional retinal
detachment increases in height, extending both anteriorly and posteriorly. Radial detachments
and more complex configurations of retinal detachments are less common.
Stage 5: Total Retinal Detachment
Typically retinal detachments are tractional, but may occasionally be exudative. They are
usually funnel shaped. Funnel configuration permits a subdivision of this stage. The funnel is
divided into anterior and posterior parts. When open, both anteriorly and posteriorly the
detachment often has a concave configuration to the optic disc. A second frequent configura‐
tion is one where the funnel is narrow in both the anterior and posterior aspects, and the
detached retina is located just behind the lens. A third less common type is where the funnel
is open anteriorly but narrowed posteriorly. Least common is a funnel that is narrow anteriorly
and open posteriorly.
‘Threshold' and 'Pre-threshold' categories of ROP severity were also developed as a result of
the CRY-ROP findings [35,36]. ‘Threshold ROP’, as a subdivision of ROP Stage 3, was associ‐
ated with an approximate 50% risk of blindness if untreated. These definitions have prognostic
importance, as 47% of threshold ROP categorisations culminated in retinal detachment [37].
3.4. “Plus” and “Pre-Plus” disease
The terms ‘Pre-plus and Plus disease’ denote increased venous dilation and arteriolar tortuos‐
ity of the posterior retinal vessels, which often lead to increased ROP severity [35-38]. These
may be accompanied by vitreous haze, iris vascular engorgement and inadequate dilation of
pupils
3.4.1. ”Plus” disease
Progressive vascular incompetence occurring along with the change at the edge of the
abnormally developing retinal vasculature may have additional signs indicating the severity
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of active ROP that can occur. These include venous dilatation and arteriolar tortuosity of the
posterior retinal vessels and may later increase in severity to include iris vascular engorgement,
poor papillary dilatation and vitreous haze. This group of supplementary signs was referred
to as ‘plus’ disease in the ICROP original classification. Subsequent refinement from clinical
trials has resulted in diagnosis of plus disease that can be made if sufficient vascular dilatation
and tortuosity are present in at least 2 quadrants of the eye. A+sign is added to the ROP stage
number where there is plus disease present. For example stage 3 ROP combined with posterior
vascular dilatation is written as ‘stage 3+ROP’. Progression may be rapid where ROP is located
in zone I or posterior zone II with plus disease present.
In the CRY-ROP study, significant retinal venous dilation and arteriolar tortuosity in all 4
vascular arcade quadrants served as diagnostic criteria for ‘Plus disease’[35-38]. However.
currently, changes in at least 2 quadrants are required for the diagnosis of ‘plus disease’ [51]
representing a terminological modification with implications for screening and treatment
decisions.
3.4.2. “Pre-Plus” disease
This has been a more recent addition to classification. Abnormal dilatation and tortuosity of
posterior pole vessels that demonstrate more than normal arterial and venous tortuosity, but
are insufficient for the diagnosis of plus disease is termed ‘preplus’ disease [8,51]. These
changes may over time progress to plus disease as vessels dilate and become more tortuous.
Despite absence of simultaneous manifestation, these symptoms are likely indicators of ROP
progression and the ‘Pre-plus disease’ category may be a useful indicator of sudden increases
in ROP activity.
3.5. Aggressive Posterior ROP (AP-ROP)
This is an uncommon rapidly progressing severe form of ROP, termed AP-ROP. Not included
in the original ICROP classification, it has recently been defined by ICROP revisited as
aggressive posterior ROP and is noted for its rapid progression to stage 5 ROP if not treated
[34]. It has been referred to as type II ROP and Rush disease. The characteristic features of this
type of ROP are the posterior location, prominence of plus disease and ill defined nature of
the retinopathy.
AP-ROP is observed most commonly in zone I, but can occur in posterior zone II. Early in the
development of AP-ROP, the posterior pole vessels show increased vascular dilatation and
tortuosity in all 4 quadrants that is out of proportion to the degree of retinopathy peripherally.
These changes progess rapidly. Shunting does not occur soley at the junction of the avascular
and vascular retina but occurs from vessel to vessel within the retina. This can make AP-ROP
difficult to distinguish arterioles and venules owing to significant dilatation of both vessel
types. There may also be haemorrhages at the junction of the vascular and avascular retina.
AP-ROP is deceptively featureless and does not usually progress through the classic stages 1-3
[40,9], appearing as a flat network of neovascularisation at the junction between the vascular‐
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isaed and nonvascularised retina. It typically extends circumferentially and is often accompa‐
nied by a circuimferential vessel. The use of a 20-D condensing lens instead of a 25-D lens in
indirect ophthalmoscopy may help distinguish the featureless neovascularisation.
On the basis of this evidence it was concluded that when the characteristics of rapidly
progressing disease are observed, or when aggressive posterior ROP is present, the baby
should be monitored closely and screening should be undertaken at least weekly [39].
4. Investigations of retinopathy of prematurity: A chronological overview
of change, development and future directions
Effective investigation of ROP is dependent on reliable classification. However, as we have
mentioned, ROP classification is not a static entity and is subject to evolutionary change
resulting from research findings, modifications to practice, technological advances and
terminological refinements. Accordingly, standard screening should be performed more
frequently, perhaps on a weekly basis [8,39].
Determining and maintaining optimal oxygen saturation levels in preterm infants has
remained something of a challenge because data regarding early mortality and long-term
neuro-developmental outcomes resulting from effects of different oxygen saturation ranges
are lacking [23,33]. The CRYO-ROP study found that the rate of progression of ROP (mean ±
standard error) was faster in eyes with an unfavourable outcome (8.2 ± 1.2 days between first
observation of ROP to pre-threshold) compared with those with a favourable outcome (12.3 ±
1.2 days), suggesting that in some situations even twice-weekly examinations are not frequent
enough [36,37].
The findings from a meta-analysis of infants with postmenstrual ages of < or=32 week
published in 2010 indicated an association between early low levels of oxygen saturation and
reduced risk for severe ROP among and late high oxygen saturation the effect of oxygen on
the development and progression of ROP is not straight forward. Ongoing investigation is
necessary to understand the relationships among oxygen concentration, variability in oxygen
concentration, and timing of oxygen delivery. Low oxygen saturation appears to decrease the
risk of severe ROP in preterm newborns when administered during the first few weeks after
birth. High oxygen saturation seems to reduce the risk at later postmenstrual ages [32].
However, individual clinical studies have not been conclusive.
A recent study by the Benefits of Oxygen Saturation Targeting (BOOST) Collaborative Group,
evaluated the effects of targeting an oxygen saturation of 85 to 89%, as compared with a range
of 91 to 95%, on disability-free survival at 2 years in 2,448 infants born before 28 weeks’
gestation in three international randomized, controlled trials [8]. Halfway through the trials,
the oximeter-calibration algorithm was revised. Recruitment was stopped early when an
interim analysis showed an increased rate of death at 36 weeks in the group with a lower
oxygen saturation [8]. The rate of death was significantly higher in the lower-target group than
in the higher-target group (23.1% vs. 15.9%; relative risk in the lower-target group, 1.45; 95%
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confidence interval (CI), 1.15 to 1.84; P=0.002) [8]. Oxygen saturation levels below 90% in
extremely preterm infants was associated with an increased risk of death [8]. Although the
lower targeted saturation group had a significantly reduced incidence of ROP, the infants also
had a significant increase in the rate of developing necrotizing enterocolitis [8].
5. Evidence to inform investigations
The first  evidence of  successful  treatment came from the multi-centre CRYO-ROP study
reported in 1988 [35]. The CRYO-ROP study reported findings after 3 months, then at 1,
3.5, 5.5, 10 and 15 years. Unfavourable outcomes (defined by ROP in the posterior retina
and retinal detachment) were less in the treated group than in the untreated group at every
time point [35-38].
The percentage of eyes with unfavourable outcomes increased over time in both groups from
25.1% at one year to 30.0% at 15 years for treated eyes, compared with 44.7% vs 51.9% for
untreated eyes [35-38]. CRYO-OP study data, describing the natural history of ROP, are
probably the most comprehensive, with current understanding of ROP based largely on the
findings of this study. Indeed, it is apparent that the CRYO-ROP study findings have influ‐
enced redefinition of ROP classification and as noted, this has implications for investigations,
screening and treatment as well as identification of risk factors, clinical course of ROP and
outcomes.
However, while outcomes of treatment in the CRYO-ROP study were superior to the untreated
controls, they are perceived less than ideal [42]. Outcomes among treated patients were
frequently poor, with 21.8% progression to macular distortion or retinal detachment and long-
term loss of vision. Cryotherapy did not benefit neonates with stage 4 ROP with partial retinal
detachment [42]. Over the longer term, even eyes with favorable anatomic outcomes still had
poor vision. ROP located in Zone 1, young gestational age, multiple births, birth outside
hospital, low birth weight, white race, plus disease (based on 4 affected eye quadrants), stage
3, >6 clock hour stage 3, and iris vessel dilatation were associated with an unfavorable anatomic
outcome [42].
Subsequent to the theory that supplemental oxygen therapy was an important factor in the
causal chain of ROP, randomized controlled trial findings indicated that restricting oxygen
might result in a lower incidence of severe ROP [43,44], but at a cost of increased mortali‐
ty [41].  Indeed, current evidence suggests that it  is  unadvisable to target oxygen-satura‐
tion concentrations below 90% in infants born prior to 28 weeks’ gestation [46]. However,
after seven decades of investigation, knowledge regarding optimal concentrations of oxygen
required to balance risk in favor of avoiding adverse effects of both hyperoxia and hypoxia
remains  inadequate  with  no  'safe'  level  of  supplementation  identified  [1]  the  clinically
appropriate range for oxygen saturation in preterm infants remains unknown. In the absence
of  complete  consensus  over  the  oxygen issue,  including a  definition  of  optimal  oxygen
concentration’ [39], it  is apparent that new approaches to the investigation and preven‐
tion of ROP are required [45-48].
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Figure 1. Courtesy of Hoag Levins. Clarity Medical Solutions. [72]
6. Current screening for ROP
An audit of UK ophthalmologists in 1999 established that although many of the 1995 Guideline
recommendations were followed, practice varied in relation to when screening should stop
and at what stage ROP should be treated [49]. Concerns were also expressed that the recom‐
mendations in the 1995 Guideline resulted in too many babies being screened, causing a heavy
workload for ophthalmologists and distress to babies receiving unnecessary retinal examina‐
tions [33-35].
Key recommendations for good practice in the UK were published in 2008 by the Royal College
of Paediatrics and Child Health and Royal College of Ophthalmologists [49].These were based
largely on ICROP revisited publication [34], findings from the CRY-OP study [38] and the Early
Treatment for Retinopathy of Prematurity study [53].
Babies of less than 32 weeks gestational age (up to 31 weeks and 6 days) or less than 1501g
birth weight should be screened for ROP [49]. One criterion to be met for inclusion [49]: Babies
of less than 31 weeks gestational age (up to 30 weeks and 6 days) or less than 1251g birth weight
must be screened for ROP. Ophthalmological notes should be made after each ROP examina‐
tion, detailing zone, stage, and extent in terms of clock hours of any ROP and the presence of
any pre-plus or plus disease [49]. These notes should include a recommendation for the timing
of the next examination (if any) and be kept with the baby’s medical record [32]. Comfort care
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techniques (e.g. administering sucrose solution, nesting, swaddling and use of a pacifier)
during the screening examination may be considered [49]. Babies with aggressive ROP (as
defined in ICROP revisited) should be treated as soon as possible and within 48 hours. ROP
requiring treatment but which is not aggressive posterior ROP should normally be treated
within 48-72 hours [49].
The current screening guideline of ROP in the United States calls for dilated fundus examina‐
tion by indirect ophthalmoscopy for all premature infants below 30 week gestational age or
less than 1500g birth weight with the first examination performed by 31 week postmenstrual
age or by 4 weeks chronologic age, with additional examinations performed repeatedly
thereafter to detect late stage ROP requiring treatment [54]. Additional screening for older or
larger babies is recommended at the discretion of the attending neonatologist [54].
Risk of sight-threatening ROP developing is considered to be minimal beyond 37 weeks
postmenstrual age although any decision to cease screening certain babies before this point in
time must be considered with caution. Examination of data from the CRYO-ROP study
indicated that babies developing stage 1 or 2 ROP in zone III were at very low risk of developing
sight-threatening ROP [55,56]. Investigations for serious ROP should be between 33 and 39
weeks post-conceptional age, while realizing that there is a degree of individual variability in
the development of retinal vasculature [56].
Figure 2. Courtesy of Tygerberg Children’s Hospital. [71]
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Risk of sight defect is regarded as minimal when regression occurs in babies with moderate
ROP, with vascularisation of the retina spreading into zone III. However, it was shown that in
3% of babies, regression and zone III vascularisation had still not occurred by 3 months post
term [56]. Therefore, the UK Guideline Development Group decided criteria for termination
of screening should be when signs of regression of active ROP are apparent as opposed to
vascularisation [49]. Signs of ROP regression have been defined by the ICROP revisited
publication as lack of increase in severity, complete or partial resolution, reduction of pre-plus/
plus disease, transgression of vessels through the demarcation line and the commencement of
the process of replacement of active ROP lesions by scar tissue [51]. The signs of regression
should be confirmed by at least two examinations [49]. In babies without ROP, eye examina‐
tions may be stopped when vascularisation has extended into zone III, usually after 36 weeks
post-conceptional age [57].
Babies with ROP that did not require treatment can have screening stopped when clear
regression is seen on 2 successive examinations [57]. Babies that required treatment for ROP
and babies diagnosed with stage 3 ROP, which resolved spontaneously, require ophthalmic
review at least until 5 years of age [57]. Babies with stages 1 or 2 ROP can have routine vision
screening, unless there is specific concern [49]. It should be noted that the process of regression
may differ between individuals and ophthalmologists should err on the side of caution when
they believe that there is still the possibility of sight-threatening ROP [49].
Until recently, universally accepted treatment criteria of ‘threshold’ ROP have been used and
there is a requirement for new studies using pre-threshold treatment criteria [49]. The UK
recommendations were drawn up with the intention not to negate use of clinical judgment by
experienced and competent ophthalmologists [49].
As with the classification, the screening for ROP is constantly evolving. Screening investiga‐
tions include frequent retinal examinations of at-risk preterm infants [57]. Delaying or
postponing a screening examination could mean that the window of opportunity for treatment
is missed [58,62].
7. Future screening
Newly developed ROP screening and prediction methods based on post-natal weight gain and
IGF-1 levels can predict infants who are at high risk for ROP. These infants may be monitored
more closely while those identified to be at low risk may be spared unnecessary diagnostic
procedures. ROP evaluations and weekly weight measurements from birth to postmenstrual
week 36 were entered into a computer-based surveillance system.
A prospective study of 50 preterm infants with a mean gestational age of 26 weeks was
conducted to validate a surveillance algorithm for detecting infants at risk for proliferative
ROP [59]. Weekly measures of body weight and (IGF-I) level from birth until postmenstrual
age 36 weeks were compared using the Weight, insulin like growth factor I (IGF-1), Neonatal
Retinopathy of Prematurity (WINROP) algorithm [59]. Gestational age, birth weight, and IGF
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binding protein 3 level are entered. An alarm is raised if any of the variables indicate a certain
degree of negative deviation [59]. The WINROP algorithm identified all infants (100%
sensitivity) who were diagnosed with proliferative ROP 1. No infants with no alarm or with
alarm at low risk developed proliferative ROP. Alarm at high risk before postmenstrual age
32 weeks was raised for 22 of 50 infants (44%); 9 of these infants developed proliferative ROP
(54% specificity), of whom 8 were treated [60]. It was concluded that the WINROP algorithm
may be a useful modification for ROP screening [59].
In another study using WINROP a total of 1706 infants with a median gestational age of 28
weeks (range, 22-31 weeks) and median birth weight of 1016 g (range, 378-2240 g) were
included in the study analysis [60]. An alarm occurred in 1101 infants (64.5%), with a median
time from birth to alarm of 3 weeks (range, 0-12 weeks) and from alarm to treatment of 8 weeks
(range, 1 day to 22 weeks). The sensitivity of WINROP was 98.6% and the negative predictive
value was 99.7%. Two infants with type 1 ROP requiring treatment after 40 weeks' postmenst‐
rual age did not receive an alarm [60].
In a Mexican patient population, the WINROP algorithm correctly predicted severe retinop‐
athy of prematurity in 84.7% of extremely preterm infants and correctly identified only 26.6%
of infants in whom severe retinopathy of prematurity did not develop [61]. These findings
suggest that potential differences exist among preterm infants with retinopathy of prematurity
in different regions of the world.
The WINROP algorithm was recently tested using a retrospective cohort study in the South
East of Scotland [63]. Anonymised clinical data were uploaded to the online WINROP site,
and infants at risk of developing severe ROP were identified. The results using WINROP were
Figure 3. Courtesy of Minas Hambardzumyan. [73]
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compared with the actual ROP screening outcomes. Infants with incomplete weight data were
included in the whole group, but were excluded from a subgroup analysis of infants with
complete weight data. In addition, data were manipulated to test whether missing weight data
points in the early neonatal period would lead to loss of sensitivity of the algorithm. The
WINROP algorithm had 73% sensitivity for detecting infants at risk of severe ROP when all
infants were included and 87% when the complete weight data subgroup was analysed.
Manipulation of data from the complete weight data subgroup demonstrated that one or two
missing weight data points in the early postnatal period lead to loss of sensitivity performance
by WINROP [63]. It was concluded that the WINROP program offers a non-invasive method
of identifying infants at high risk of severe ROP and also identifying those not at risk. However,
for WINROP to function optimally, it has to be used as recommended and designed, namely
weekly body weight measurements are required [63].
Figure 4. Courtesy of BIOPHOTONICS [74].
8. Digital imaging
Interpretation of digital images have been found to have good inter/intra-reader reliability
[64,65] which enhances its potential for use in what is termed ‘telemedicine’ [49]. The use of
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digital photographic retinal images that are captured and sent for remote interpretation is a
developing approach to ROP screening however, outcomes comparison between large-scale
operational digital-imaging systems with remote interpretation versus binocular indirect
ophthalmoscopy have not been published.
While there is not sufficient research evidence to demonstrate that wide field digital fundus
photography is as effective as the indirect ophthalmoscope for ROP screening, some UK
screeners already the technique ‘RetCam’ is of choice although the cost is likely to remain a
deterrent for many units [49]. However, training of operators is an important issue and no
studies have yet demonstrated that cameras operated by non-ophthalmologists are as sensitive
at detecting ROP as the indirect ophthalmoscope in the hands of a skilled ophthalmologist [66].
Accurate assessment of ROP is essential in ensuring correct and timely treatment of this
potentially blinding condition [67,68]. Current modes of assessment are based upon clinical
grading by expert examination of retinal changes. However, this may be subjective, unreliable
and difficult and there has been significant interest in alternative means of measurement. These
have been made possible through technological advancements in image capture and analysis
as well as progress in clinical research, highlighting the specific importance of the plus disease
category in ROP [68]. Progress in these two fields has highlighted the potential for digital image
analysis of plus disease to be used as an objective, reliable and valid measurement of ROP.
However, with the potential benefits, there are significant challenges such as in image capture,
segmentation, measurement of vessel width and tortuosity [68].
The standard method for diagnosis of ROP has been bedside indirect ophthalmoscopy for
both routine clinical care and clinical trials. With this approach, the examiner's interpreta‐
tions of the clinical findings are transcribed onto grading sheets, rather than a photograph‐
ic record of the actual retinal features. One limitation to this approach is that the examiner's
interpretation of fundus findings is presumed to be correct without opportunity for review.
Photographic  documentation  would  serve  to  confirm  diagnosis  and  distinguish  true
therapeutic  failure  from  poor  outcome  caused  by  incomplete  treatment  [68].  Thus,
telemedicine may offer a solution to many of the current geographic and resource problems
preventing  a  comprehensive  ROP  screening  program  throughout  the  world.  Future
additions  to  telemedicine  could  comprise  weight-gain  algorithms  combined  with  other
reliable quantitative data such as IGF-1 levels.
Furthermore, computer-based image analysis using quantitative methods has the potential to
improve the objectivity of plus disease diagnosis [69]. Plus disease diagnosis is critical for
decision-making in ROP, as it is necessary for threshold disease and sufficient for type 1 ROP.
Plus disease is defined as abnormal arteriolar tortuorsity and venular dilation in the posterior
pole greater than that of a standard published photograph, which was selected by expert
consensus for the CRYO-ROP study and is still widely used [69]. During the past 10 years,
several computer-based systems have been developed for ROP, particularly for detection of
plus disease. This has potential to improve clinical ROP management [69,70]. However, more
large-scale, robust clinical trials are still required to provide the necessary evidence to inform
optimum investigation and screening for all aspects of ROP.
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RISA analysis:
Figure 5. Image documented via RETCAM from (Gelman et al., 2005) [70] : a).(a) Retina (b) Choose the vessel. (c) High‐
light the vessel. (d) & (e) Mark the vessel. (f) Tortuosity index :Measure actual vessel length, measure the length of
point 1 to point 9, divide actual length by length of points 1&9
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9. Management of retinopathy of prematurity medical management
9.1. Optimising oxygen therapy
Although incubators for infants had been developed around the mid-nineteenth century, it
was not until the 1920s that neonates were grouped together for specialist care in early neonatal
intensive care units. Special Care Baby Units became established in many hospitals in the 1940s,
although incubators were expensive, oxygen, heat, humidity were considered desirable but
influence of such parameters on clinical outcomes were anecdotal – hard clinical data were
lacking.
The development of neonatal care, technology and research has reduced gestational age
compatible with life to less than 24 weeks with additional challenges in the prevention of ROP.
Identifying a safe level of oxygen therapy to prevent the development of ROP in such babies
without increasing mortality has been the subject of numerous clinical trials [45, 76-82].
The efficacy and safety of supplemental oxygen therapy for premature infants with pre-
threshold  ROP  was  evaluated  in  the  STOP-ROP  trial  [43].  Infants  with  oxygen  satura‐
tions maintained at less than 94% with pre-threshold ROP were assigned to conventional
oxygen of 89-94%, or supplemental oxygen with target saturations 96-99%. Supplemental
oxygen did not increase progression to threshold ROP or reduce the numbers of infants
requiring laser photocoagulation or cryotherapy. There was some suggestion in post-hoc
subgroup analysis that infants without plus disease may be more responsive to supplemen‐
tal oxygen therapy [43].
The HOPE study analysed data from the STOP-ROP trial, including infants who were excluded
from STOP ROP with oxygen saturations >94% prior to enrolment [83]. The HOPE-ROP cohort
were of a higher gestational age, progressing to threshold ROP in 25% of cases, compared to
46% of the STOP-ROP cohort. Logistic regression analysis identified oxygen saturation at the
time of pre-threshold diagnosis to be of borderline significance once gestational age, race, post-
menstrual age at diagnosis, zone I disease, and plus disease had been accounted for [83].
The NeOProM study is a prospective meta-analysis collaboration seeking to recruit 5,000
extremely premature neonates to detect rates of death and disability, including visual out‐
comes from ROP measured at 18 months gestation [85]. Results are expected from this study
in 2014.
Increasing neonatal mortality with oxygen restriction suggests that ROP cannot be prevented
by oxygen restriction alone in premature infants.
9.2. ROP: When to treat
The “ET-ROP” was a landmark study evaluating the timing of treatment of ROP [86], with
some concern that a proportion of neonates would receive treatment for ROP that would
regress spontaneously and therefore carry an excess risk of surgical complications. The ET-
ROP trial was a nationally funded, prospective, randomized, controlled clinical trial that
sought to identify clinical criteria to predict those neonates who had the highest risk for an
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adverse visual or structural outcome [86], and evaluate the implications for timing of ablative
treatment for ROP. Natural history data of ROP from the CRYO-ROP study was used to
formulate an algorithm, randomization occurred when the risk was calculated to be 15% or
greater (high risk pre-threshold), either to early ablative treatment or observation until
threshold or regression. Functional outcomes were assessed by grating visual acuity at 9
months gestation, and structural outcomes were evaluated through fundus examination with
unfavourable outcome defined as retinal fold involving the macula, retinal detachment
involving the macula, retrolental tissue obscuring posterior pole.
499 high risk pre-threshold neonates with ROP were randomized. The ET-ROP study identi‐
fied that peripheral retinal ablation should be considered in any eye with zone I ROP with plus
disease (any stage), zone I ROP stage 3 with or without plus, or zone II stage 2 or 3 ROP with
plus disease (two quadrants, or six clock hours). Those neonates with type II ROP should be
considered for treatment when progression to threshold or any of the above criteria are met.
These treatment criteria have been influential and are incorporated into many national
standards for ROP screening, defining thresholds for treatment [86,87].
9.3. ROP: How to treat
9.3.1. Cryotherapy
Reduction of VEGF production may be achieved with peripheral retinal ablation using
cryotherapy. The (CRYO-ROP) studies evaluated the safety and efficacy of cryotherapy for
stage 3 ROP. A randomised, controlled clinical trial evaluated 9,751 neonates, 291 of whom
developed severe ROP. Cryotherapy reduced the incidence of unfavourable outcomes and
improved functional outcomes in neonates with threshold ROP [88]. No intraoperative, or
immediate post-operative complications were identified, and no deaths were attributed to
cryotherapy treatment [89]. Risk reduction was found to be around 50% [35,36], and conse‐
quently recommendations were made for cryotherapy treatment to both eyes of neonates with
stage 3 ROP in zone I [36]. The CRYO-ROP study was terminated prematurely due to signif‐
icant treatment benefit with cryotherapy at the 3 month interim analysis [89,90]. A structural
and functional benefit of cryotherapy was demonstrated after evaluation 3 years post-
intervention [91]. 10 year follow-up revealed a clear protective effect of cryotherapy in ROP in
the long-term in neonates with ROP [92]. New retinal detachments were identified in 15 year
follow up [93].
The CRYO-ROP study provided numerous insights into the natural history of ROP, risk factors
[94] and racial predilection [95], predictors of disease severity [96], prognosis [37,56,97],
symmetry or concordance of disease between eyes [98], functional outcomes [99-101], involu‐
tional change [56], myopia [102], strabismus [103] and ocular comesis [104]. Cryotherapy did
not benefit neonates with stage 4 ROP with partial retinal detachment [105]. The CRYO-ROP
study identified a small loss of peripheral field around 6.4 degrees compared to controls [106]
in eyes with severe ROP [107], and an increased incidence of myopia [108].
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9.3.2. Laser photocoagulation
9.3.2.1. Anterior to the ridge laser photocoagulation (Avascular retina)
Zone I ROP owing to posterior location and area of ischaemic or avascular retina cannot be
treated with cryotherapy alone. Diode laser photocoagulation anterior to the neovascular ridge
in neonates with threshold zone I ROP has been demonstrated effective treatment, in contrast
to cryoablation [109]. Further studies have demonstrated diode laser photocoagulation for
stage 3 ROP to be at least as effective as cryotherapy treatment, with 40 of 42 eyes of eyes
regressing after a single laser treatment; only 1 eye progressed to stage 4 ROP.
A study of 48 eyes found argon laser photocoagulation to be effective in the management of
threshold ROP in zone I or posterior zone II with confluent laser to the avascular retina, with
only 7 eyes progressing to stage 4A retina or beyond, without any recorded complications
attributable to laser itself [110]. The mechanism of argon laser photocoagulation in stage 3 ROP
is thought to be through reduced peripheral retinal oxygen consumption and reduction of
VEGF.
Laser photocoagulation may be achieved with scattered laser; near-confluent [111] or confluent
laser burns [112]. Confluent laser burns anterior to the ridge through 360 degrees in threshold
ROP demonstrated low rates of progression to stage 4 or 5 ROP (6%), with mean spherical
equivalent of-3.80DS in infants [112]. Near confluent laser photocoagulation anterior to the
neovascular ridge prevented progression in 4 of 7 eyes with zone I ROP, and all with zone II
ROP [111]. A larger combined retrospective and prospective study evaluated 107 neonates
with threshold ROP compared near-confluent with scatter diode laser, finding that near-
confluent laser photocoagulation was superior to scatter laser in reducing progression in eyes
with both zone I and zone 2 ROP [113]. However, randomized trials of anterior to the ridge
laser photocoagulation have not been conducted to evaluate the relative efficacy of burn
distribution; it is likely that large studies are required to detect a difference as rate of progres‐
sion to stage 4 and 5 ROP are low.
9.3.2.2. Ridge laser photocoagulation
A randomized, interventional comparative study evaluated the efficacy of argon laser
photocoagulation to the neovascular ridge and anterior avascular retina versus laser to the
avascular retina only [114] in neonates with threshold ROP. No immediate benefit of ridge
laser photocoagulation was apparent, but longterm analysis is awaited. A retrospective study
of anterior and ridge laser photocoagulation for threshold ROP with a favourable anatomical
outcome in 96% of eyes, although long-term sequalae were not reported [115]. No vitreous
haemorrhage was reported in this series. The additional benefit of direct laser photocoagula‐
tion of the neovascular ridge in ROP remains unproven [116].
9.3.2.3. Posterior to the ridge laser (Vascular retina)
Posterior to the ridge argon laser photocoagulation is a surgical approach that considers the
presence of ischaemic retina posterior to the neovascular ridge, with or without confirmation
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of ischaemia with fluorescein angiography. Posterior to the ridge laser has been demonstrated
in a non-comparative case series (no control arm) to be effective in the management of stage 3
ROP in zone II, where only 2 of 18 eyes progressed to stage 4A ROP. None developed stage
4B [117]. Aggressive posterior ROP (AP-ROP) may benefit from posterior argon laser photo‐
coagulation in neonates with late stage 3 or stage 4A ROP following unsuccessful treatment
to the avascular retina in threshold stage 3 disease [109]. The benefit of FFA guided posterior
to the ridge laser has not been evaluated.
9.3.3. Anti-VEGF agents
9.3.3.1. Bevacizumab
Bevacizumab (Avastin) is a humanized monoclonal antibody raised against vascular endo‐
thelial growth factor (VEGF) isoform A, directly inhibiting angiogenesis. Avastin was origi‐
nally developed and licensed for treatment of metastatic colorectal cancer, non-small cell lung
cancer, renal carcinoma and glioblastoma multiforme. Avastin has been used off-label for the
treatment of choroidal neovascularisation secondary to age-related macular degeneration,
degenerative myopia, retinal vein occlusion, diabetic macular oedema and other disorders
characterised by retinal or choroidal vascular abnormalities.
Retinopathy of prematurity is associated with high levels of VEGF within the vitreous and the
rationale of administering intravitreal biologic drugs to inactivate it was considered as early
as 2008. Avastin for stage 3 ROP with plus disease in zone I or posterior zone II was shown in
a limited, non-comparative series to prevent progression of ROP with a single intravitreal
injection of Avastin [118]. The BEAT-ROP study was the first prospective, randomized
controlled trial comparing laser photocoagulation with intravitreal Avastin for zone I or
posterior zone II stage 3+ROP, finding a significant benefit for zone I disease with Avastin,
with continued vascularisation compared with conventional laser photocoagulation [119].
Laser photocoagulation for Zone I ROP involves extensive retinal ablation, with increased risk
of visual field loss and secondary myopia.
Some studies have evaluated the outcome of combined laser and bevacizumab (0.25mg)
for zone I ROP, finding all 18 study eyes demonstrated regression of plus disease without
recurrence and vascularisation retina in zone I  in  all  patients.  The authors  argue that  a
lower dose of bevacizumab may be used if combined with laser photocoagulation, reduced
recurrence than with monotherapy and preservation of central field [120]. Others demon‐
strate  the use bevacizumab as monotherapy (0.625mg),  demonstrating efficacy in zone I
stage 3 ROP [119,121]. Other groups demonstrate efficacy with rescue intravitreal bevacizu‐
mab  following  laser  photocoagulation  in  aggressive  posterior  ROP  [122].  The  optimal
dosage  for  ROP  remains  to  be  determined  [123].  Late  recurrence  of  ROP  in  has  been
reported with subsequent late tractional retinal detachment following initial regression of
ROP  [124].  Bevacizumab  is  associated  with  less  significant  myopia  and  astigmatism
compared to laser [125].
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Systemic absorption of bevacizumab is of concern, and although short-term follow-up studies
and surveillance has not demonstrated any attributable systemic morbidity or mortality, this
remains unproven. Fellow eyes demonstrate response to contralateral bevacizumab in ROP,
suggesting significant systemic absorption of the drug [126].
9.3.3.2. Ranibizumab
Ranibizumab (Lucentis) is a monoclonal antibody directed against all  isoforms of VEGF.
It  has  been used off-label  in  retinopathy of  prematurity,  although data  is  more  limited
compared  to  that  of  bevacizumab.  Experience  from  studies  with  ranibizumab  in  adult
disorders,  particularly  neovascular  age-related  macular  degeneration,  has  demonstrated
fractionally increased systemic risk with bevacizumab versus ranibizumab but not enough
to  reach  statistical  significance.  Logic  would  therefore  consider  ranibizumab  in  the
treatment of ROP, particularly zone I ROP in which the ETROP study demonstrated a 55%
treatment failure rate.
Combined laser-ranibizumab in this patient group has demonstrated promising control of
stage 3 zone I ROP with regression in all cases, in a non-comparative series of 34 eyes [127].
Combination laser-ranibizumab has been demonstrated effective in the treatment of aggres‐
sive, posterior ROP, although this was a limited series of two neonates [128]. Three year
outcomes with ranibizumab monotherapy in a series of six eyes with high-risk pre-threshold
or threshold ROP with plus disease demonstrated complete regression of neovascularisation
with a single treatment and continued vascularisation [129]. No attributable ocular or systemic
side-effects were recorded [129]. Single case series of efficacy add limited evidence in favour
of ranibizumab in ROP [130] Late retinal detachment in stage 3 zone I ROP has been reported
similar to bevacizumab after initial neovascular regression [131].
Different pharmacokinetic and pharmacodynamic properties of ranibizumab and bevacizu‐
mab require randomized clinical studies to compare the efficacy in AP-ROP, threshold ROP.
Ocular effects and systemic absorption, and non-inferiority demonstrated between ranibizu‐
mab and bevacizumab in neovascular AMD cannot be extrapolated to neonates with ROP.
Long-term surveillance is required to document systemic outcomes in neonates treated with
anti-VEGF agents for ROP to detect late adverse effects not currently encompassed in short-
term published trial data.
9.3.3.3. Pegaptinib
Pegaptinib (Macugen, 0.3mg in 0.02mls) has been evaluated for stage 3+ROP with adjunctive
laser photocoagulation in a randomized controlled clinical trial found to be more efficacious
than laser alone [132]. Recurrence of neovascularisation was noted at 14.4 weeks with bevaci‐
zumab, at 15.1 weeks with pegaptinib with laser, and 5.9 weeks with laser alone [133]. Risk
factors for recurrence, the interval for follow-up examination, and length of time required for
follow-up is unknown [133].
Ophthalmology - Current Clinical and Research Updates306
10. Surgical management
Surgical intervention is necessary for patient with stage 4 partial retinal detachments, which
may or may not involve the fovea, or those with open or closed funnel retinal detachments.
Surgical approaches include scleral buckle, vitrectomy and combined vitrectomy-lensectomy.
Factors affecting surgical outcome of stage 4 and 5 ROP have been examined and a poorer
surgical outcome may be associated with vitreous haze, active neovascularisation and plus
disease [134]. Plus disease was identified as the most significant factor associated with failed
retinal reattachment; additional surgery or intravitreal anti-VEGF agents may be considered
pre-operatively to improve outcome in this group [134].
Outcomes from neonates from the ET-ROP study who stage 4 or 5 ROP were generally poor.
Vitreoretinal surgery was associated with macular attachment in 16 of 48 eyes (33%). Normal
acuity was maintained in 21% of eyes after 4a retinal detachment. Stage 5 ROP was associated
with good anatomical but poor functional outcome [135].
10.1. Scleral buckling
Stage 4 ROP, partial retinal detachment with or without foveal involvement (stage 4a/ stage
4b respectively) may be treated with lens-sparing vitrectomy with or without the use of
external tamponade with a scleral buckle. Studies on the outcome of scleral buckles for stage
4 ROP are limited, and limited study numbers, without randomization make conclusions on
the efficacy of scleral buckles difficult. Variability in surgical experience and expertise with
scleral buckles in stage 4 ROP makes comparison between studies difficult. Long-term outcome
in patients from the ETROP trial with retinal detachments (stage 4a/4b/5 ROP) were reported
[87]. Vitrectomy with or without scleral buckle resulted in macular attachment in 17 of 50 eyes,
scleral buckle only achieved macular attachment in 6 of 9 eyes after 7 years. This data was from
multiple centres and surgeons, and not randomized making cross comparison difficult. A high
proportion of retinal detachments (20%) were not classified [87].
A small retrospective interventional case series identified 21 eyes with stage 4 ROP, comparing
anatomical outcomes of lens-sparing vitrectomy versus combined lens-sparing vitrectomy and
scleral buckle [135]; 12 undergoing combined LSV and SB, and 9 LSV alone. The authors
conclude that scleral buckle adds little to the success or failure of LSV with similar outcomes
in each group [135], but this small series may not have been adequately powered to detect a
difference in treatment outcome. Another retrospective series of 16 eyes who underwent scleral
buckling for stage 4 ROP reported anatomical success of 100% in stage 4a and 50% in stage 4b
ROP [136]. The buckle was removed in 11 of 12 infants, and mean refraction was-8.68 diopters.
There was no control group in this study, but evidence was offered of reducing progression
to stage 5 ROP [136].
A further single-surgeon series of 8 neonates who underwent scleral buckling for stage 4a ROP
conclude efficacy in preventing progression of retinal detachment, although this study was
non-comparative [137].
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Scleral buckling requires further procedures under general anaesthetic to reduce the tension
of the buckle, or remove it altogether. The tension created by the buckle causes axial myopia
(reduced by 5.5 dioptres after division of the buckle), and removal or adjustment of tension
necessitates repeat refraction to prevent ametropic amblyopia [138]. Removal of scleral buckle
has been demonstrated without resulting retinal detachment or vitreous traction [139].
Anatomical success in patients with repair of stage 4 or 5 ROP may not equate simply to visual
improvement in such studies [134]. This is supported by evidence from a systematic review
of outcomes of surgical intervention for ROP [140], which demonstrated poor vision in many
patients regardless of retinal attachment status. There is difficulty in many studies of meas‐
uring low visual acuity in infants; this may not be achieved by grating acuity that is often used
as an output in many ROP series.
Large, multicentre, long term studies with randomization are required to determine the
efficacy of scleral buckling, but variations in surgical expertise and preference may be
prohibitive. It is unlikely that meta-analysis will be valid for this reason. A systematic review
of anatomical and visual function outcomes in ROP with vitrectomy and scleral buckle
identified a wide variation of retinal reattachment rates between centres of 0.8 to 90% [140].
Earlier surgery was associated with a superior retinal reattachment rate, although longer
follow-up was associated with increasing anatomical failure [140].
10.2. Vitrectomy
Evaluating surgical outcomes in ROP is difficult due to the long interval between intervention
and reliable recording of monocular visual acuities, variability in surgical technique and
experience, and the effect of neurological co-morbidity in clinical evaluation. Many studies are
retrospective case series with non-standardised follow-up intervals, and no control arms which
limits inferences of efficacy.
Early data from the CRYO-ROP study evaluated the functional outcome of neonates with stage
5 ROP (total retinal detachment) who underwent lensectomy-vitrectomy procedures before
one year of age, comparing this cohort with infants who did not. Almost all infants had visual
acuity of light perception or worse at 5 years [141].
Further studies demonstrate more promising results. A single-centre retrospective case series
reported 37 eyes treated with LSV for stage 4A and 4B ROP, with follow up of 5 years. 63%
had measureable visual acuity, 18% had form vision, and 19% had light perception vision or
worse [142]. Further similar series evaluated LSV in the setting of progressive posterior-type
stage 4A ROP with plus disease, documenting low anatomical success of LSV in progressive
posterior stage 4A ROP, particularly associated with plus disease [143].
A consecutive, non-randomized, retrospective series comparing outcomes patients with stage
4 ROP treated with scleral buckle or lens-sparing vitrectomy found that LSV was associated
with retinal reattachment in 72% of patients versus 31% of SB patients. At final follow-up, after
further procedures, LSV and SB were found comparable in outcome as a first procedure. LSV
was favoured in this study as more effective as a single procedure to stop stage 4 ROP [144].
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The advent of anti-VEGF agents has led to widespread adjuvant use prior to vitrectomy in
vasoproliferative disease to augment surgical outcome. Stage 4A ROP with plus disease has
poorer surgical outcomes, and many reports have evaluated the benefit of bevacizumab prior
to vitrectomy in these patients [145-148]. Several reports have documented the apparent pro-
fibrotic effect of bevacizumab with contraction of fibrovascular membranes which may
increased tractional retinal detachment [149] and require surgical treatment. Case reports
document acute retinal fibrosis 1 day following bevacizumab despite acute resolution of the
vascular component, with centripetal contraction of fibrovascular tissue and retinal detach‐
ment [150]. One series evaluated the efficacy of intravitreal bevacizumab 72 hour prior to
vitrectomy or laser, finding improved visualisation in high risk ROP [151]. This finding has
been demonstrated in other series [87,154], with no adverse effects attributable to bevacizumab
in the short-term [152].
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